Advanced search
Publication Cover
COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 16, 2019 - Issue 2
Submit an article Journal homepage
1,149
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies

Jill A. OharWake Forest University, Winston-Salem, NC, USA; Correspondence[email protected]
View further author information
,
Sanjay SharmaSunovion Pharmaceuticals Inc., Marlborough, MA, USAView further author information
,
Thomas GoodinSunovion Pharmaceuticals Inc., Marlborough, MA, USAView further author information
,
Alyssa BowlingSunovion Pharmaceuticals Inc., Marlborough, MA, USAView further author information
,
Barry PriceSunovion Pharmaceuticals Inc., Marlborough, MA, USAView further author information
,
Ayca Ozol-GodfreySunovion Pharmaceuticals Inc., Marlborough, MA, USAView further author information
&
Shahin SanjarSunovion Pharmaceuticals Inc., Marlborough, MA, USAView further author information
 show all
Pages 133-139 | Received 12 Feb 2019, Accepted 23 Apr 2019, Published online: 27 Jun 2019

References

  • Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68. doi: 10.1183/09031936.05.00035205.
  • Hanania NA, Celli BR, Donohue JF, Martin, UJ. Bronchodilator reversibility in COPD. Chest. 2011;140(4):1055–63. doi: 10.1378/chest.10-2974.
  • Albert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P, Celli BR, Coxson HO, Crim C, Lomas DA, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701–8. doi: 10.1136/thoraxjnl-2011-201458.
  • Rossi A, Khirani S, Cazzola M. Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis. 2008;3(4):521–9. doi: 10.2147/COPD.S1353.
  • Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, Tashkin D. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011;12:6.
  • Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest. 2003;123(5):1441–9.
  • Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–64.
  • Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D. FLIGHT1 and FLIGHT2: Efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–79. doi: 10.1164/rccm.201505-1048OC.
  • Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65. doi: 10.1164/rccm.201204-0596PP.
  • Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–9.
  • Mahler DA, Witek TJ, Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103.
  • Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man WD. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi: 10.1016/S2213-2600(14)70001-3.
  • Global Initiative for Chronic Obstructive Lung Disease Inc. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD; 2019. Available from: http://goldcopd.org/.
  • Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31(4):742–50. doi: 10.1183/09031936.00129607.
  • Tashkin DP, Ferguson GT, Clerisme-Beaty E, Vob F, Buhl R. Lung-function response to tiotropium + olodaterol in patients with COPD with β-agonist reversibility. Am J Respir Crit Care Med. 2016;193:A6808.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.